Ded personal page - To The Moon

Ded

Ded

No personal profile

2Follow

0Followers

0Topic

0Badge

2021-08-13

$Catalyst Pharmaceuticals(CPRX)$Go go goooo

2021-06-28

$High Tide Inc.(HITI)$Go go go

2021-06-28

$ChargePoint Holdings Inc.(CHPT)$Go go go

2021-06-23

$Express,(EXPR)$let’s go![Miser]

2021-06-23

$ChargePoint Holdings Inc.(CHPT)$Go go go![Cool]

2021-06-23

$Histogenics(OCGN)$?

2021-06-18

$High Tide Inc.(HITI)$[Spurting]

2021-06-18

Nice[Strong]

ChargePoint’s Network Effects Will Make It the Next ‘Shell’

2021-06-17

Wow

Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO

2021-06-17

$ChargePoint Holdings Inc.(CHPT)$[Cool]

2021-06-17

[Miser]

Crypto Die-Hards Built a $90 Billion Wall Street on the Internet

2021-06-17

$ChargePoint Holdings Inc.(CHPT)$One of the largest and oldest EV charging network provider in the world!

2021-06-16

$Catalyst Pharmaceuticals(CPRX)$Go go go

2021-06-15

$Catalyst Pharmaceuticals(CPRX)$Holddddd

2021-06-15

$LightPath(LPTH)$Anyone holding?

2021-06-14

$LightPath(LPTH)$?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573642293610153","uuid":"3573642293610153","gmtCreate":1610579672328,"gmtModify":1623683742865,"name":"Ded","pinyin":"ded","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.17","exceedPercentage":"80.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":897985423,"gmtCreate":1628868418462,"gmtModify":1676529881769,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","text":"$Catalyst Pharmaceuticals(CPRX)$Go go goooo","images":[{"img":"https://static.tigerbbs.com/577232879fad6fb52b8d989dde2a5e0f","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897985423","isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150117323,"gmtCreate":1624889581362,"gmtModify":1703847192981,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","text":"$High Tide Inc.(HITI)$Go go go","images":[{"img":"https://static.tigerbbs.com/b60aab03b6e83f72afec21985dfc94b6","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150117323","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150107201,"gmtCreate":1624888915403,"gmtModify":1703847152020,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150107201","isVote":1,"tweetType":1,"viewCount":702,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121954237,"gmtCreate":1624451373229,"gmtModify":1703837046918,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","text":"$Express,(EXPR)$let’s go![Miser]","images":[{"img":"https://static.tigerbbs.com/7e33febab7ea9f082d82d94a90198e2b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121954237","isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121956357,"gmtCreate":1624451221979,"gmtModify":1703837042054,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go![Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121956357","isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121953962,"gmtCreate":1624451043756,"gmtModify":1703837037682,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","text":"$Histogenics(OCGN)$?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121953962","isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166454932,"gmtCreate":1624023649726,"gmtModify":1703826842413,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","text":"$High Tide Inc.(HITI)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/9856b4aee333fe53f91b104be5e2001d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166454932","isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166453874,"gmtCreate":1624023510798,"gmtModify":1703826834050,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Nice[Strong]&nbsp;","listText":"Nice[Strong]&nbsp;","text":"Nice[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166453874","repostId":"1181667218","repostType":2,"repost":{"id":"1181667218","kind":"news","pubTimestamp":1624008124,"share":"https://ttm.financial/m/news/1181667218?lang=&edition=fundamental","pubTime":"2021-06-18 17:22","market":"us","language":"en","title":"ChargePoint’s Network Effects Will Make It the Next ‘Shell’","url":"https://stock-news.laohu8.com/highlight/detail?id=1181667218","media":"investorplace","summary":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May a","content":"<p><b>ChargePoint</b>&nbsp;(NYSE:<b><u>CHPT</u></b>) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed420b8993199e014fc4d87c875c9dd5\" tg-width=\"300\" tg-height=\"169\"><span>Source: YuniqueB / Shutterstock.com</span></p>\n<p>The catalyst? There are a few of them —</p>\n<ul>\n <li>Recharged growth trade on lower bond yields</li>\n <li>Reinvigorated optimism about EVs and the charging network buildout</li>\n <li>New, rather impressive products from ChargePoint</li>\n</ul>\n<p>This will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.</p>\n<p>Here’s why.</p>\n<p>ChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version of<b>Shell</b>(NYSE:<b><u>RDS-A</u></b>, NYSE:<b><u>RDS-B</u></b>) or<b>Exxon</b>(NYSE:<b><u>XOM</u></b>) by 2030.</p>\n<p>On the surface, this company looks like all other EV charging companies.</p>\n<p>ChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.</p>\n<p>Basically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …</p>\n<p>CHPT Stock: Network Effects Set ChargePoint Apart</p>\n<p>Where ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.</p>\n<p>It’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.</p>\n<p>Its size is especially significant because of network effects.</p>\n<p>Of ChargePoint’s commercial clients, more than 60% of&nbsp;<b>Fortune 500</b>&nbsp;companies employ ChargePoint charging stations at their corporate offices. If companies such as<b>Facebook</b>(NASDAQ:<b><u>FB</u></b>),<b>Netflix</b>(NASDAQ:<b><u>NFLX</u></b>),<b>Salesforce</b>(NYSE:<b><u>CRM</u></b>),<b>Microsoft</b>(NASDAQ:<b><u>MSFT</u></b>) and<b>Adobe</b>(NASDAQ:<b><u>ADBE</u></b>) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.</p>\n<p>ChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.</p>\n<p>From a consumer-facing perspective, ChargePoint is also setting itself up for future success.</p>\n<p>The company hasteamed up with auto makerslike Mercedes-owner&nbsp;<b>Daimler AG</b>(OTCMKTS:<b><u>DMLRY</u></b>) and<b>BMW</b>(OTC:<b><u>BMWYY</u></b>) tointegrate the locations of its charging stationsinto in-car navigation systems.</p>\n<p>ChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.</p>\n<p>Again, it all comes down to ChargePoint’s unmatched network effects.</p>\n<p>Which is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.</p>\n<p>Naturally, that would mean huge upside potential for CHPT stock.</p>\n<p>Which is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChargePoint’s Network Effects Will Make It the Next ‘Shell’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChargePoint’s Network Effects Will Make It the Next ‘Shell’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHPT":"ChargePoint Holdings Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181667218","content_text":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe catalyst? There are a few of them —\n\nRecharged growth trade on lower bond yields\nReinvigorated optimism about EVs and the charging network buildout\nNew, rather impressive products from ChargePoint\n\nThis will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.\nHere’s why.\nChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version ofShell(NYSE:RDS-A, NYSE:RDS-B) orExxon(NYSE:XOM) by 2030.\nOn the surface, this company looks like all other EV charging companies.\nChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.\nBasically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …\nCHPT Stock: Network Effects Set ChargePoint Apart\nWhere ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.\nIt’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.\nIts size is especially significant because of network effects.\nOf ChargePoint’s commercial clients, more than 60% of Fortune 500 companies employ ChargePoint charging stations at their corporate offices. If companies such asFacebook(NASDAQ:FB),Netflix(NASDAQ:NFLX),Salesforce(NYSE:CRM),Microsoft(NASDAQ:MSFT) andAdobe(NASDAQ:ADBE) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.\nChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.\nFrom a consumer-facing perspective, ChargePoint is also setting itself up for future success.\nThe company hasteamed up with auto makerslike Mercedes-owner Daimler AG(OTCMKTS:DMLRY) andBMW(OTC:BMWYY) tointegrate the locations of its charging stationsinto in-car navigation systems.\nChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.\nAgain, it all comes down to ChargePoint’s unmatched network effects.\nWhich is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.\nNaturally, that would mean huge upside potential for CHPT stock.\nWhich is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163370080,"gmtCreate":1623860662640,"gmtModify":1703821852932,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163370080","repostId":"2143792542","repostType":4,"repost":{"id":"2143792542","kind":"news","pubTimestamp":1623854323,"share":"https://ttm.financial/m/news/2143792542?lang=&edition=fundamental","pubTime":"2021-06-16 22:38","market":"us","language":"en","title":"Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2143792542","media":"Yahoo Finance","summary":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the t","content":"<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows <a href=\"https://laohu8.com/S/AONE\">one</a> of the disease's most debilitating symptoms: cognitive decline.</p>\n<p>In a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.</p>\n<p>Ricks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.</p>\n<p>\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in <a href=\"https://laohu8.com/S/AONE.U\">one</a> trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.</p>\n<p>Biogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.</p>\n<p>\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"</p>\n<p>\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"</p>\n<p>\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"</p>\n<p>The approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.</p>\n<p>\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.</p>\n<p>\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.</p>\n<h2>'There are huge unmet needs'</h2>\n<p>Biogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.</p>\n<p>\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"</p>\n<p>The backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"</p>\n<p>Speaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.</p>\n<p>\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"</p>\n<p>\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","LLY":"礼来"},"source_url":"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143792542","content_text":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows one of the disease's most debilitating symptoms: cognitive decline.\nIn a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.\nRicks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.\n\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"\nTwo trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in one trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.\nBiogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.\n\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"\n\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"\n\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"\nThe approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.\n\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.\n\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.\n'There are huge unmet needs'\nBiogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.\n\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"\nThe backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"\nSpeaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.\n\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"\n\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163344565,"gmtCreate":1623860630857,"gmtModify":1703821850965,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$[Cool]","images":[{"img":"https://static.tigerbbs.com/9b459b32a44edb67cce1e75099dad8b3","width":"828","height":"1590"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/163344565","isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163340105,"gmtCreate":1623860435407,"gmtModify":1703821839513,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163340105","repostId":"1160929405","repostType":4,"repost":{"id":"1160929405","kind":"news","pubTimestamp":1623844146,"share":"https://ttm.financial/m/news/1160929405?lang=&edition=fundamental","pubTime":"2021-06-16 19:49","market":"sh","language":"en","title":"Crypto Die-Hards Built a $90 Billion Wall Street on the Internet","url":"https://stock-news.laohu8.com/highlight/detail?id=1160929405","media":".bloomberg","summary":"Money manager Vladimir Vishnevskiy can earn anegative interest ratefor holding a European government","content":"<p>Money manager Vladimir Vishnevskiy can earn anegative interest ratefor holding a European government bond. Or he can pocket the annual equivalent of a 20% yield for locking money up in one of the wilder corners of the crypto market, known as decentralized finance, or DeFi.</p>\n<p>He decided to go for the 20%. “You can’t get those yields in the traditional space,” says the co-founder of Swiss-based St. Gotthard Fund Management, which runs a portfolio designed to squeeze income out of crypto assets. The strategy is so new that even Wall Street pros may have trouble wrapping their heads around it. Take what you might know about Bitcoin—that it’s a digital currency that exists only on an online ledger governed by computer code. Now make it even more mind-bending, and imagine the code isn’t just recording transactions. It’s running lending platforms, insurers and financial markets with little human intermediation. That’sDeFi.</p>\n<p>Traders like Vishnevskiy can collect yields by committing in the form of crypto tokens the capital that’s needed to make these disembodied and largely unregulated financial institutions run. At the peak last month, investors put in as much as $86 billion into various DeFi programs, compared with just under $1 billion a year ago, DeFi Pulse data show.</p>\n<p>It’s a young, volatile, and hack-prone system. (One of the first decentralized projects, a fund called the DAO, was the victim of aspectacular $55 million theftby someone taking advantage of a flaw in its code to siphon off funds.) And for now, it’s mostly a crypto world built for thecrypto universe. The decentralized lenders are largely taking crypto deposits to make loans to people looking for leverage on crypto bets; the decentralized exchanges are used for trading crypto coins; the decentralized insurers cover crypto hacks.</p>\n<p>The big yields investors can earn are denominated not in dollars or euros but in often-obscure tokens. Critics of DeFi say some projects can resemble a Ponzi scheme: Early investors depend on others piling into tokens that still have limited real-world utility. If returns are high, it’s largely because of investors’ voracious appetite for more digital assets. And since DeFi projects don’t need to live in any physical location, they’re difficult to regulate, making the space vulnerable to scams and money laundering schemes. Still, DeFi’s advocates think the technology has the power to open up markets and build new kinds of financial products.</p>\n<p>To see how a DeFi program works, look atSushiSwap, a decentralized cryptocurrency exchange that started last year. It’s based on the code of another DeFi exchange calledUniswap. Like any exchange—from better-known crypto trading apps such asCoinbaseto stock markets likeNasdaq—SushiSwap depends on liquidity, or the ability to make sure buyers can find the tokens they want and sellers can get a price they think is fair. To do that in a decentralized way, SushiSwap creates liquidity pools that pair any two coins that traders might want to swap—for example, Ethereum, thesecond-most-popular cryptocurrencyand DeFi’s backbone, and the exchange’s own token, Sushi.</p>\n<p>Investors like Vishnevskiy buy both tokens and then temporarily lock them into the pool, where they’re available to traders. An algorithm adjusts prices of both tokens to reflect relative changes in demand. The exchange also charges a fee for trading. When Vishnevskiy gets his tokens back, he also gets a portion of the fees generated from transactions made in the pool, as well as free additional Sushi tokens. (The added Sushi tokens can be earned on other trading pairs, not only those involving Sushi.) That, the exchange’s software surmises, amounts to an annualized 20% yield.</p>\n<p>Other DeFi protocols may pay yields to people who make their crypto available for someone else to borrow. For example, traders might want to borrowstablecoins—tokens whose value is linked to that of a traditional currency such as the dollar—to buy more Bitcoin on platforms that don’t take traditional currencies.</p>\n<p>If that sounds complicated, it is. Yields in DeFi are mostly projected from recent market trends and could drop quickly. Some investors who call themselves yield farmers are constantly moving their money trying to generate income, but crypto transaction costs called “gas” fees can eat up profits. Moreover, the cryptocurrencies these yields get paid in can fluctuate wildly in value. When Bitcoin slid as much as 10% on one recent day, popular DeFi coins such as Uniswap’s fell almost 20%.</p>\n<p>Other risks that come with any cryptocurrency still apply:Regulatory scrutinywill probably grow, which might shut down or hamper some projects and blow up the value of associated tokens. Founders of DeFi projects who’ve hoarded the coins created to run them could suddenly cash out, causing prices to drop. SushiSwap’s pseudonymous creator, Chef Nomi, sold tokens worth roughly $13 million in September before reversing course amid community outrage.</p>\n<p>“You can’t get those yields in the traditional space”</p>\n<p>The history of crypto is filled with cautionary tales about investments riding a wave of hype and then falling apart. Around 2018, so-called initial coin offerings raised billions of dollars for projects, most of which turned out to be duds. DeFi converts say the difference now is that applications such as exchanges and lenders are generating revenue, even if just from crypto speculation. Uniswap, which announces its user statistics in real time, had trading volume of $813 million in one recent 24-hour period, generating $1.8 million in fees for those staking their tokens in its liquidity pool.</p>\n<p>What about the value of the tokens many DeFi projects give out? These coins aren’t exactly equity and don’t always confer any direct claim to profits. Often they give holders voting rights on the future of the project; investors may be hoping that as the protocols they’re associated with grow in popularity, so will the coins. But some DeFi platforms might not be as successful as they seem. Aleksander Kloda, who co-manages a DeFi fund at Nickel Digital Asset Management, says participation may be driven less by the value of a service than by the promise of free tokens. “In the short term, they can really make the picture a lot more difficult to read,” he says. “The logic is not quite correct if the volumes are only there because of the additional motivation the protocol gives you to participate.” As an investor, he tries to identify projects that have built up sustainable volume even without tantalizing yields.</p>\n<p>Advocates of DeFi say the idea is still in its infancy, and it could eventually broaden its uses and reach into more traditional areas of finance. Their dream is a financial system run on the internet that doesn’t involve a credit officer at a JPMorgan branch, or a Citadel Securities investing in high-frequency infrastructure tokeep stock trading liquid.</p>\n<p>But Elaine Ou, a blockchain engineer at Global Financial Access, argues there’s nothing wrong with DeFi being used only for crypto trading, either. “Look at Vegas and Macau—part of the reason they’re so valuable is that they allow you to do what other jurisdictions have banned,” says Ou, who alsowritesfor Bloomberg Opinion. “It is possible to build an entire industry up around speculation.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto Die-Hards Built a $90 Billion Wall Street on the Internet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto Die-Hards Built a $90 Billion Wall Street on the Internet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 19:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-16/defi-platforms-with-names-like-sushiswap-aim-to-be-nasdaq-for-crypto><strong>.bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Money manager Vladimir Vishnevskiy can earn anegative interest ratefor holding a European government bond. Or he can pocket the annual equivalent of a 20% yield for locking money up in one of the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-16/defi-platforms-with-names-like-sushiswap-aim-to-be-nasdaq-for-crypto\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-16/defi-platforms-with-names-like-sushiswap-aim-to-be-nasdaq-for-crypto","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160929405","content_text":"Money manager Vladimir Vishnevskiy can earn anegative interest ratefor holding a European government bond. Or he can pocket the annual equivalent of a 20% yield for locking money up in one of the wilder corners of the crypto market, known as decentralized finance, or DeFi.\nHe decided to go for the 20%. “You can’t get those yields in the traditional space,” says the co-founder of Swiss-based St. Gotthard Fund Management, which runs a portfolio designed to squeeze income out of crypto assets. The strategy is so new that even Wall Street pros may have trouble wrapping their heads around it. Take what you might know about Bitcoin—that it’s a digital currency that exists only on an online ledger governed by computer code. Now make it even more mind-bending, and imagine the code isn’t just recording transactions. It’s running lending platforms, insurers and financial markets with little human intermediation. That’sDeFi.\nTraders like Vishnevskiy can collect yields by committing in the form of crypto tokens the capital that’s needed to make these disembodied and largely unregulated financial institutions run. At the peak last month, investors put in as much as $86 billion into various DeFi programs, compared with just under $1 billion a year ago, DeFi Pulse data show.\nIt’s a young, volatile, and hack-prone system. (One of the first decentralized projects, a fund called the DAO, was the victim of aspectacular $55 million theftby someone taking advantage of a flaw in its code to siphon off funds.) And for now, it’s mostly a crypto world built for thecrypto universe. The decentralized lenders are largely taking crypto deposits to make loans to people looking for leverage on crypto bets; the decentralized exchanges are used for trading crypto coins; the decentralized insurers cover crypto hacks.\nThe big yields investors can earn are denominated not in dollars or euros but in often-obscure tokens. Critics of DeFi say some projects can resemble a Ponzi scheme: Early investors depend on others piling into tokens that still have limited real-world utility. If returns are high, it’s largely because of investors’ voracious appetite for more digital assets. And since DeFi projects don’t need to live in any physical location, they’re difficult to regulate, making the space vulnerable to scams and money laundering schemes. Still, DeFi’s advocates think the technology has the power to open up markets and build new kinds of financial products.\nTo see how a DeFi program works, look atSushiSwap, a decentralized cryptocurrency exchange that started last year. It’s based on the code of another DeFi exchange calledUniswap. Like any exchange—from better-known crypto trading apps such asCoinbaseto stock markets likeNasdaq—SushiSwap depends on liquidity, or the ability to make sure buyers can find the tokens they want and sellers can get a price they think is fair. To do that in a decentralized way, SushiSwap creates liquidity pools that pair any two coins that traders might want to swap—for example, Ethereum, thesecond-most-popular cryptocurrencyand DeFi’s backbone, and the exchange’s own token, Sushi.\nInvestors like Vishnevskiy buy both tokens and then temporarily lock them into the pool, where they’re available to traders. An algorithm adjusts prices of both tokens to reflect relative changes in demand. The exchange also charges a fee for trading. When Vishnevskiy gets his tokens back, he also gets a portion of the fees generated from transactions made in the pool, as well as free additional Sushi tokens. (The added Sushi tokens can be earned on other trading pairs, not only those involving Sushi.) That, the exchange’s software surmises, amounts to an annualized 20% yield.\nOther DeFi protocols may pay yields to people who make their crypto available for someone else to borrow. For example, traders might want to borrowstablecoins—tokens whose value is linked to that of a traditional currency such as the dollar—to buy more Bitcoin on platforms that don’t take traditional currencies.\nIf that sounds complicated, it is. Yields in DeFi are mostly projected from recent market trends and could drop quickly. Some investors who call themselves yield farmers are constantly moving their money trying to generate income, but crypto transaction costs called “gas” fees can eat up profits. Moreover, the cryptocurrencies these yields get paid in can fluctuate wildly in value. When Bitcoin slid as much as 10% on one recent day, popular DeFi coins such as Uniswap’s fell almost 20%.\nOther risks that come with any cryptocurrency still apply:Regulatory scrutinywill probably grow, which might shut down or hamper some projects and blow up the value of associated tokens. Founders of DeFi projects who’ve hoarded the coins created to run them could suddenly cash out, causing prices to drop. SushiSwap’s pseudonymous creator, Chef Nomi, sold tokens worth roughly $13 million in September before reversing course amid community outrage.\n“You can’t get those yields in the traditional space”\nThe history of crypto is filled with cautionary tales about investments riding a wave of hype and then falling apart. Around 2018, so-called initial coin offerings raised billions of dollars for projects, most of which turned out to be duds. DeFi converts say the difference now is that applications such as exchanges and lenders are generating revenue, even if just from crypto speculation. Uniswap, which announces its user statistics in real time, had trading volume of $813 million in one recent 24-hour period, generating $1.8 million in fees for those staking their tokens in its liquidity pool.\nWhat about the value of the tokens many DeFi projects give out? These coins aren’t exactly equity and don’t always confer any direct claim to profits. Often they give holders voting rights on the future of the project; investors may be hoping that as the protocols they’re associated with grow in popularity, so will the coins. But some DeFi platforms might not be as successful as they seem. Aleksander Kloda, who co-manages a DeFi fund at Nickel Digital Asset Management, says participation may be driven less by the value of a service than by the promise of free tokens. “In the short term, they can really make the picture a lot more difficult to read,” he says. “The logic is not quite correct if the volumes are only there because of the additional motivation the protocol gives you to participate.” As an investor, he tries to identify projects that have built up sustainable volume even without tantalizing yields.\nAdvocates of DeFi say the idea is still in its infancy, and it could eventually broaden its uses and reach into more traditional areas of finance. Their dream is a financial system run on the internet that doesn’t involve a credit officer at a JPMorgan branch, or a Citadel Securities investing in high-frequency infrastructure tokeep stock trading liquid.\nBut Elaine Ou, a blockchain engineer at Global Financial Access, argues there’s nothing wrong with DeFi being used only for crypto trading, either. “Look at Vegas and Macau—part of the reason they’re so valuable is that they allow you to do what other jurisdictions have banned,” says Ou, who alsowritesfor Bloomberg Opinion. “It is possible to build an entire industry up around speculation.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163384303,"gmtCreate":1623859847202,"gmtModify":1703821799294,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>One of the largest and oldest EV charging network provider in the world!","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>One of the largest and oldest EV charging network provider in the world!","text":"$ChargePoint Holdings Inc.(CHPT)$One of the largest and oldest EV charging network provider in the world!","images":[{"img":"https://static.tigerbbs.com/466c3d46da0dda56f0d97f0c3f2c382d","width":"750","height":"2127"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163384303","isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163976294,"gmtCreate":1623858729018,"gmtModify":1703821728454,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go go","text":"$Catalyst Pharmaceuticals(CPRX)$Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163976294","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187598957,"gmtCreate":1623757827379,"gmtModify":1703818297431,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Holddddd","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Holddddd","text":"$Catalyst Pharmaceuticals(CPRX)$Holddddd","images":[{"img":"https://static.tigerbbs.com/083322a79309248d9f044389624cd746","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187598957","isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187506471,"gmtCreate":1623757532093,"gmtModify":1703818286487,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>Anyone holding?","listText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>Anyone holding?","text":"$LightPath(LPTH)$Anyone holding?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/187506471","isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184080748,"gmtCreate":1623678068284,"gmtModify":1704208433893,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>?","listText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>?","text":"$LightPath(LPTH)$?","images":[{"img":"https://static.tigerbbs.com/4abe0d4edbfe1fa4237db9703d7a4f56","width":"828","height":"1590"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184080748","isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":187506471,"gmtCreate":1623757532093,"gmtModify":1703818286487,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>Anyone holding?","listText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>Anyone holding?","text":"$LightPath(LPTH)$Anyone holding?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/187506471","isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163344565,"gmtCreate":1623860630857,"gmtModify":1703821850965,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$[Cool]","images":[{"img":"https://static.tigerbbs.com/9b459b32a44edb67cce1e75099dad8b3","width":"828","height":"1590"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/163344565","isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163384303,"gmtCreate":1623859847202,"gmtModify":1703821799294,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>One of the largest and oldest EV charging network provider in the world!","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>One of the largest and oldest EV charging network provider in the world!","text":"$ChargePoint Holdings Inc.(CHPT)$One of the largest and oldest EV charging network provider in the world!","images":[{"img":"https://static.tigerbbs.com/466c3d46da0dda56f0d97f0c3f2c382d","width":"750","height":"2127"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163384303","isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150117323,"gmtCreate":1624889581362,"gmtModify":1703847192981,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","text":"$High Tide Inc.(HITI)$Go go go","images":[{"img":"https://static.tigerbbs.com/b60aab03b6e83f72afec21985dfc94b6","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150117323","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150107201,"gmtCreate":1624888915403,"gmtModify":1703847152020,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150107201","isVote":1,"tweetType":1,"viewCount":702,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166454932,"gmtCreate":1624023649726,"gmtModify":1703826842413,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","text":"$High Tide Inc.(HITI)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/9856b4aee333fe53f91b104be5e2001d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166454932","isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":897985423,"gmtCreate":1628868418462,"gmtModify":1676529881769,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","text":"$Catalyst Pharmaceuticals(CPRX)$Go go goooo","images":[{"img":"https://static.tigerbbs.com/577232879fad6fb52b8d989dde2a5e0f","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897985423","isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121954237,"gmtCreate":1624451373229,"gmtModify":1703837046918,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","text":"$Express,(EXPR)$let’s go![Miser]","images":[{"img":"https://static.tigerbbs.com/7e33febab7ea9f082d82d94a90198e2b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121954237","isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121956357,"gmtCreate":1624451221979,"gmtModify":1703837042054,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go![Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121956357","isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121953962,"gmtCreate":1624451043756,"gmtModify":1703837037682,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","text":"$Histogenics(OCGN)$?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121953962","isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166453874,"gmtCreate":1624023510798,"gmtModify":1703826834050,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Nice[Strong]&nbsp;","listText":"Nice[Strong]&nbsp;","text":"Nice[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166453874","repostId":"1181667218","repostType":2,"repost":{"id":"1181667218","kind":"news","pubTimestamp":1624008124,"share":"https://ttm.financial/m/news/1181667218?lang=&edition=fundamental","pubTime":"2021-06-18 17:22","market":"us","language":"en","title":"ChargePoint’s Network Effects Will Make It the Next ‘Shell’","url":"https://stock-news.laohu8.com/highlight/detail?id=1181667218","media":"investorplace","summary":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May a","content":"<p><b>ChargePoint</b>&nbsp;(NYSE:<b><u>CHPT</u></b>) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed420b8993199e014fc4d87c875c9dd5\" tg-width=\"300\" tg-height=\"169\"><span>Source: YuniqueB / Shutterstock.com</span></p>\n<p>The catalyst? There are a few of them —</p>\n<ul>\n <li>Recharged growth trade on lower bond yields</li>\n <li>Reinvigorated optimism about EVs and the charging network buildout</li>\n <li>New, rather impressive products from ChargePoint</li>\n</ul>\n<p>This will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.</p>\n<p>Here’s why.</p>\n<p>ChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version of<b>Shell</b>(NYSE:<b><u>RDS-A</u></b>, NYSE:<b><u>RDS-B</u></b>) or<b>Exxon</b>(NYSE:<b><u>XOM</u></b>) by 2030.</p>\n<p>On the surface, this company looks like all other EV charging companies.</p>\n<p>ChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.</p>\n<p>Basically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …</p>\n<p>CHPT Stock: Network Effects Set ChargePoint Apart</p>\n<p>Where ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.</p>\n<p>It’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.</p>\n<p>Its size is especially significant because of network effects.</p>\n<p>Of ChargePoint’s commercial clients, more than 60% of&nbsp;<b>Fortune 500</b>&nbsp;companies employ ChargePoint charging stations at their corporate offices. If companies such as<b>Facebook</b>(NASDAQ:<b><u>FB</u></b>),<b>Netflix</b>(NASDAQ:<b><u>NFLX</u></b>),<b>Salesforce</b>(NYSE:<b><u>CRM</u></b>),<b>Microsoft</b>(NASDAQ:<b><u>MSFT</u></b>) and<b>Adobe</b>(NASDAQ:<b><u>ADBE</u></b>) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.</p>\n<p>ChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.</p>\n<p>From a consumer-facing perspective, ChargePoint is also setting itself up for future success.</p>\n<p>The company hasteamed up with auto makerslike Mercedes-owner&nbsp;<b>Daimler AG</b>(OTCMKTS:<b><u>DMLRY</u></b>) and<b>BMW</b>(OTC:<b><u>BMWYY</u></b>) tointegrate the locations of its charging stationsinto in-car navigation systems.</p>\n<p>ChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.</p>\n<p>Again, it all comes down to ChargePoint’s unmatched network effects.</p>\n<p>Which is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.</p>\n<p>Naturally, that would mean huge upside potential for CHPT stock.</p>\n<p>Which is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChargePoint’s Network Effects Will Make It the Next ‘Shell’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChargePoint’s Network Effects Will Make It the Next ‘Shell’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHPT":"ChargePoint Holdings Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181667218","content_text":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe catalyst? There are a few of them —\n\nRecharged growth trade on lower bond yields\nReinvigorated optimism about EVs and the charging network buildout\nNew, rather impressive products from ChargePoint\n\nThis will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.\nHere’s why.\nChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version ofShell(NYSE:RDS-A, NYSE:RDS-B) orExxon(NYSE:XOM) by 2030.\nOn the surface, this company looks like all other EV charging companies.\nChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.\nBasically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …\nCHPT Stock: Network Effects Set ChargePoint Apart\nWhere ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.\nIt’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.\nIts size is especially significant because of network effects.\nOf ChargePoint’s commercial clients, more than 60% of Fortune 500 companies employ ChargePoint charging stations at their corporate offices. If companies such asFacebook(NASDAQ:FB),Netflix(NASDAQ:NFLX),Salesforce(NYSE:CRM),Microsoft(NASDAQ:MSFT) andAdobe(NASDAQ:ADBE) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.\nChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.\nFrom a consumer-facing perspective, ChargePoint is also setting itself up for future success.\nThe company hasteamed up with auto makerslike Mercedes-owner Daimler AG(OTCMKTS:DMLRY) andBMW(OTC:BMWYY) tointegrate the locations of its charging stationsinto in-car navigation systems.\nChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.\nAgain, it all comes down to ChargePoint’s unmatched network effects.\nWhich is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.\nNaturally, that would mean huge upside potential for CHPT stock.\nWhich is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163370080,"gmtCreate":1623860662640,"gmtModify":1703821852932,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163370080","repostId":"2143792542","repostType":4,"repost":{"id":"2143792542","kind":"news","pubTimestamp":1623854323,"share":"https://ttm.financial/m/news/2143792542?lang=&edition=fundamental","pubTime":"2021-06-16 22:38","market":"us","language":"en","title":"Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2143792542","media":"Yahoo Finance","summary":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the t","content":"<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows <a href=\"https://laohu8.com/S/AONE\">one</a> of the disease's most debilitating symptoms: cognitive decline.</p>\n<p>In a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.</p>\n<p>Ricks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.</p>\n<p>\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in <a href=\"https://laohu8.com/S/AONE.U\">one</a> trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.</p>\n<p>Biogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.</p>\n<p>\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"</p>\n<p>\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"</p>\n<p>\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"</p>\n<p>The approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.</p>\n<p>\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.</p>\n<p>\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.</p>\n<h2>'There are huge unmet needs'</h2>\n<p>Biogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.</p>\n<p>\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"</p>\n<p>The backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"</p>\n<p>Speaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.</p>\n<p>\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"</p>\n<p>\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","LLY":"礼来"},"source_url":"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143792542","content_text":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows one of the disease's most debilitating symptoms: cognitive decline.\nIn a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.\nRicks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.\n\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"\nTwo trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in one trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.\nBiogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.\n\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"\n\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"\n\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"\nThe approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.\n\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.\n\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.\n'There are huge unmet needs'\nBiogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.\n\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"\nThe backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"\nSpeaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.\n\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"\n\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163340105,"gmtCreate":1623860435407,"gmtModify":1703821839513,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163340105","repostId":"1160929405","repostType":4,"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163976294,"gmtCreate":1623858729018,"gmtModify":1703821728454,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go go","text":"$Catalyst Pharmaceuticals(CPRX)$Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163976294","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187598957,"gmtCreate":1623757827379,"gmtModify":1703818297431,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Holddddd","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Holddddd","text":"$Catalyst Pharmaceuticals(CPRX)$Holddddd","images":[{"img":"https://static.tigerbbs.com/083322a79309248d9f044389624cd746","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187598957","isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":184080748,"gmtCreate":1623678068284,"gmtModify":1704208433893,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>?","listText":"<a href=\"https://laohu8.com/S/LPTH\">$LightPath(LPTH)$</a>?","text":"$LightPath(LPTH)$?","images":[{"img":"https://static.tigerbbs.com/4abe0d4edbfe1fa4237db9703d7a4f56","width":"828","height":"1590"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184080748","isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}